Improvement in exercise capacity despite cardiac deterioration

Noninvasive assessment of long-term therapy with amrinone in severe heart failure

Lewis A. Siegel, Thierry H. LeJemtel, Joel Strom, Carol Maskin, Robert Forman, William Frishman, John Wexler, Hillel Ribner, Edmund H. Sonnenblick

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Seven patients with severe congestive heart fallure (CHF) were treated with oral amrinone for a mean duration of 39 weeks (range 16 to 72). During the first week of therapy, exercise capacity as assessed on a treadmill using the Naughton protocol, increased substantially from 7.6 ± 4.2 to 12.1 ± 4.4 minutes (p < 0.01). At an early period of follow-up (8 to 12 weeks), a further significant increase in exercise capacity to 14.7 ± 5.0 minutes (p < 0.05) was demonstrated, while at a later follow-up exercise capacity had decreased to 11.4 ± 6.8 minutes (p < 0.05). This was still significantly greater than prior to amrinone therapy (p < 0.01). Left ventricular ejection fraction was increased from 14 ± 4 to 19 ± 4% (p < 0.05) during the first week of therapy, but was not significantly different from control at the early and late periods of follow-up. Left ventricular end-diastolic dimension index increased from control value of 43 ± 5 to 47 ± 7 mm/m2 (p < 0.01) at the late period of follow-up. Thus long-term amrinone therapy resulted in a substantial improvement in exercise capacity despite a slow, but progressive decline in cardiac performance.

Original languageEnglish (US)
Pages (from-to)1042-1047
Number of pages6
JournalAmerican Heart Journal
Volume106
Issue number5 PART 1
DOIs
StatePublished - 1983

Fingerprint

Amrinone
Heart Failure
Exercise
Exercise Therapy
Stroke Volume
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Improvement in exercise capacity despite cardiac deterioration : Noninvasive assessment of long-term therapy with amrinone in severe heart failure. / Siegel, Lewis A.; LeJemtel, Thierry H.; Strom, Joel; Maskin, Carol; Forman, Robert; Frishman, William; Wexler, John; Ribner, Hillel; Sonnenblick, Edmund H.

In: American Heart Journal, Vol. 106, No. 5 PART 1, 1983, p. 1042-1047.

Research output: Contribution to journalArticle

Siegel, LA, LeJemtel, TH, Strom, J, Maskin, C, Forman, R, Frishman, W, Wexler, J, Ribner, H & Sonnenblick, EH 1983, 'Improvement in exercise capacity despite cardiac deterioration: Noninvasive assessment of long-term therapy with amrinone in severe heart failure', American Heart Journal, vol. 106, no. 5 PART 1, pp. 1042-1047. https://doi.org/10.1016/0002-8703(83)90650-6
Siegel, Lewis A. ; LeJemtel, Thierry H. ; Strom, Joel ; Maskin, Carol ; Forman, Robert ; Frishman, William ; Wexler, John ; Ribner, Hillel ; Sonnenblick, Edmund H. / Improvement in exercise capacity despite cardiac deterioration : Noninvasive assessment of long-term therapy with amrinone in severe heart failure. In: American Heart Journal. 1983 ; Vol. 106, No. 5 PART 1. pp. 1042-1047.
@article{4ee863c90a80489093e58f7f441edba3,
title = "Improvement in exercise capacity despite cardiac deterioration: Noninvasive assessment of long-term therapy with amrinone in severe heart failure",
abstract = "Seven patients with severe congestive heart fallure (CHF) were treated with oral amrinone for a mean duration of 39 weeks (range 16 to 72). During the first week of therapy, exercise capacity as assessed on a treadmill using the Naughton protocol, increased substantially from 7.6 ± 4.2 to 12.1 ± 4.4 minutes (p < 0.01). At an early period of follow-up (8 to 12 weeks), a further significant increase in exercise capacity to 14.7 ± 5.0 minutes (p < 0.05) was demonstrated, while at a later follow-up exercise capacity had decreased to 11.4 ± 6.8 minutes (p < 0.05). This was still significantly greater than prior to amrinone therapy (p < 0.01). Left ventricular ejection fraction was increased from 14 ± 4 to 19 ± 4{\%} (p < 0.05) during the first week of therapy, but was not significantly different from control at the early and late periods of follow-up. Left ventricular end-diastolic dimension index increased from control value of 43 ± 5 to 47 ± 7 mm/m2 (p < 0.01) at the late period of follow-up. Thus long-term amrinone therapy resulted in a substantial improvement in exercise capacity despite a slow, but progressive decline in cardiac performance.",
author = "Siegel, {Lewis A.} and LeJemtel, {Thierry H.} and Joel Strom and Carol Maskin and Robert Forman and William Frishman and John Wexler and Hillel Ribner and Sonnenblick, {Edmund H.}",
year = "1983",
doi = "10.1016/0002-8703(83)90650-6",
language = "English (US)",
volume = "106",
pages = "1042--1047",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "5 PART 1",

}

TY - JOUR

T1 - Improvement in exercise capacity despite cardiac deterioration

T2 - Noninvasive assessment of long-term therapy with amrinone in severe heart failure

AU - Siegel, Lewis A.

AU - LeJemtel, Thierry H.

AU - Strom, Joel

AU - Maskin, Carol

AU - Forman, Robert

AU - Frishman, William

AU - Wexler, John

AU - Ribner, Hillel

AU - Sonnenblick, Edmund H.

PY - 1983

Y1 - 1983

N2 - Seven patients with severe congestive heart fallure (CHF) were treated with oral amrinone for a mean duration of 39 weeks (range 16 to 72). During the first week of therapy, exercise capacity as assessed on a treadmill using the Naughton protocol, increased substantially from 7.6 ± 4.2 to 12.1 ± 4.4 minutes (p < 0.01). At an early period of follow-up (8 to 12 weeks), a further significant increase in exercise capacity to 14.7 ± 5.0 minutes (p < 0.05) was demonstrated, while at a later follow-up exercise capacity had decreased to 11.4 ± 6.8 minutes (p < 0.05). This was still significantly greater than prior to amrinone therapy (p < 0.01). Left ventricular ejection fraction was increased from 14 ± 4 to 19 ± 4% (p < 0.05) during the first week of therapy, but was not significantly different from control at the early and late periods of follow-up. Left ventricular end-diastolic dimension index increased from control value of 43 ± 5 to 47 ± 7 mm/m2 (p < 0.01) at the late period of follow-up. Thus long-term amrinone therapy resulted in a substantial improvement in exercise capacity despite a slow, but progressive decline in cardiac performance.

AB - Seven patients with severe congestive heart fallure (CHF) were treated with oral amrinone for a mean duration of 39 weeks (range 16 to 72). During the first week of therapy, exercise capacity as assessed on a treadmill using the Naughton protocol, increased substantially from 7.6 ± 4.2 to 12.1 ± 4.4 minutes (p < 0.01). At an early period of follow-up (8 to 12 weeks), a further significant increase in exercise capacity to 14.7 ± 5.0 minutes (p < 0.05) was demonstrated, while at a later follow-up exercise capacity had decreased to 11.4 ± 6.8 minutes (p < 0.05). This was still significantly greater than prior to amrinone therapy (p < 0.01). Left ventricular ejection fraction was increased from 14 ± 4 to 19 ± 4% (p < 0.05) during the first week of therapy, but was not significantly different from control at the early and late periods of follow-up. Left ventricular end-diastolic dimension index increased from control value of 43 ± 5 to 47 ± 7 mm/m2 (p < 0.01) at the late period of follow-up. Thus long-term amrinone therapy resulted in a substantial improvement in exercise capacity despite a slow, but progressive decline in cardiac performance.

UR - http://www.scopus.com/inward/record.url?scp=0021029316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021029316&partnerID=8YFLogxK

U2 - 10.1016/0002-8703(83)90650-6

DO - 10.1016/0002-8703(83)90650-6

M3 - Article

VL - 106

SP - 1042

EP - 1047

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 5 PART 1

ER -